) --




) hit a new 52-week high Monday as it is currently trading at $22.20, above its previous 52-week high of $22.17 with 4.7 million shares traded as of 10:15 a.m. ET. Average volume has been 43.5 million shares over the past 30 days.

Pfizer has a market cap of $166.5 billion and is part of the

health care

sector and


industry. Shares are up 0.8% year to date as of the close of trading on Friday.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 19.6, above the average drugs industry P/E ratio of 14.9 and above the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Pfizer as a


. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full

Pfizer Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center